Nitric oxide-releasing suppositories and methods of use thereof

Abstract

To provide suppositories, and to provide methods of use thereof.SOLUTION: According to some embodiments of the present invention, provided herein is a nitric oxide (NO) releasing suppository (e.g., vaginal suppositories). Some embodiments are directed to compositions, kits, and / or methods for treating and / or preventing an infection (e.g., a viral infection). In some embodiments, a method of treating and / or preventing a viral infection in a subject in need of treating and / or preventing a viral infection is provided.SELECTED DRAWING: None

Description

[Technical Field]

[0001] Related Application Information This application claims the benefit of U.S. Provisional Patent Application No. 62 / 637,120, filed March 1, 2018, the disclosure of which is incorporated herein by reference in its entirety.

[0002] FIELD OF THE INVENTION The present invention relates generally to suppositories and methods of using the same, including methods of treating and / or preventing infections (e.g., viral infections). Summary of the Invention [Means for solving the problem]

[0003] It should be noted that aspects described with respect to one embodiment may be incorporated in a different embodiment even if not specifically described in that context. NO-releasing suppositories (e.g., vaginal suppositories) are described herein. Some embodiments are directed to compositions, kits, and / or methods for treating and / or preventing infections (e.g., viral infections). In some embodiments, methods for treating and / or preventing viral infections in a subject in need thereof are provided.

[0004] These and other aspects of the present invention will now be described in more detail with reference to other embodiments described herein. It should be understood that the present invention may be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. DETAILED DESCRIPTION OF THE INVENTION

[0005] The present invention will now be described more fully hereinafter. It should be understood, however, that the present invention may be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.

[0006] The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used in the detailed description of the invention and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly dictates otherwise.

[0007] Unless otherwise defined, all terms used herein (including technical and scientific terms) have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It will be further understood that words, such as those defined in commonly used dictionaries, should be interpreted to have a meaning consistent with their meaning in the context of this application and the related art, and should not be interpreted in an idealized or overly formal sense unless expressly defined herein. The terms used in the detailed description of the invention herein are for the purpose of describing particular embodiments only and are not intended to limit the invention. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict in terminology, the present specification controls.

[0008] Also, as used herein, "and / or" refers to and includes any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted as alternatives ("or").

[0009] Unless the context dictates otherwise, it is expressly intended that the various features of the invention described herein can be used in any combination. Moreover, the present invention also contemplates that in some embodiments of the invention, any feature or combination of features described herein can be excluded or omitted. By way of example, if the specification states that a composite comprises component A, component B, and component C, it is expressly intended that any of A, B, or C, or combinations thereof, can be omitted and removed.

[0010] As used herein, the transitional phrase "consisting essentially of" (and grammatical variations thereof) should be interpreted to include the materials or steps recited and "materials or steps that do not materially affect one or more of the basic and novel characteristics" of the claimed invention. In re Herz , 537 F.2d 549, 551-52, 190 USPQ 461, 463 (CCPA 1976) (emphasis in original); see also MPEP Section 2111.03. Thus, as used herein, the word "consisting essentially of" should not be construed as equivalent to "comprising."

[0011] As used herein, the term "about" when referring to a measurable value, such as an amount or concentration, is intended to refer to a variation of up to ±20% of the specified value, for example, but not limited to, ±10%, ±5%, ±1%, ±0.5%, or even ±0.1% of the specified value, and the specified value. For example, "about X," where X is a measurable value, is intended to encompass X and a variation of ±20%, ±10%, ±5%, ±1%, ±0.5%, or even ±0.1% of X. Ranges of measurable values ​​provided herein can encompass any other ranges and / or individual values ​​within the ranges.

[0012] As used herein, the terms "increase," "increases," "increased," "increasing," and similar terms refer to an increase in the specified parameter of at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 150%, about 200%, about 300%, about 400%, or about 500% or more.

[0013] As used herein, the term "reduce," "reduces," "reduced," "reduction," "inhibit," and similar terms refer to a reduction of at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97%, or about 100% in the specified parameter.

[0014] According to some embodiments of the present invention, provided herein are nitric oxide (NO)-releasing suppositories (e.g., vaginal suppositories). The vaginal suppositories of the present invention may be in a dosage form comprising a solid that can be inserted and / or placed into a subject's vagina and may melt, soften, and / or dissolve upon insertion and / or placement. In some embodiments, the vaginal suppositories of the present invention may be inserted into the vagina with and / or without an applicator. In some embodiments, the vaginal suppositories of the present invention may be administered digitally. In some embodiments, the vaginal suppositories may be inserted into the vagina using an applicator that complies with FDA CCS guidance and USP. In some embodiments, the vaginal suppositories of the present invention may be administered into the subject's vagina by the subject and / or may be administered to the subject without the need for an administering clinician (e.g., a physician).

[0015] In some embodiments, the suppositories of the present invention are prepared by compression or molding, or any other technique known to those skilled in the art. The suppositories of the present invention may comprise one or more (e.g., one, two, three, or four or more) active pharmaceutical ingredients dispersed and / or dissolved in one or more (e.g., one, two, three, or four or more) bases (i.e., suppository bases) and, optionally, one or more (e.g., one, two, three, or four or more) excipients. In some embodiments, the vaginal suppositories of the present invention comprise an NO-releasing active pharmaceutical ingredient (API) and a suppository base. The vaginal suppository may also comprise one or more excipients, such as a buffering agent, preservative, solvent, and / or lubricant. The excipients may not adversely alter the residence time, tolerance, and / or toxicological profile of the vaginal suppository in the vagina upon application. In some embodiments, the vaginal suppository has a composition and / or pH that is capable of and / or configured to achieve substantially total (e.g., at least about 75%) or complete (i.e., 100%) NO release from the vaginal suppository. In some embodiments, the amount of NO release from a vaginal suppository of the present invention upon administration to a subject is compared to the amount of NO release in vitro, which can optionally be tested in vitro by contact with a composition that is comparable to physiological fluids that the vaginal suppository may contact in vivo.

[0016] In some embodiments, the suppository base and / or excipients of the vaginal suppositories of the present invention may be selected to allow for easy dispersion and / or at least partial solubilization of the API (e.g., dispersion and / or solubilization of the API at low temperatures, such as below 30°C (e.g., about 30 to about 50°C, about 35 to about 40°C, or about 45 to about 50°C)). In some embodiments, the suppository base and / or excipients of the vaginal suppositories of the present invention may not promote degradation of the API and / or may not promote release of NO during manufacture and / or storage. In some embodiments, the suppository base and / or excipients of the vaginal suppositories of the present invention may maintain the amorphous form of the API and / or not promote crystallization. In some embodiments, at least a portion of the API in the vaginal suppositories of the present invention may be present in a crystalline form. In some embodiments, the vaginal suppository of the present invention and / or its suppository base and / or excipients may not alter the vaginal microflora (e.g., may not alter the number of microorganisms, pH, etc. by more than ±20% compared to the number of microorganisms, pH, etc. before administration). In some embodiments, the vaginal suppository of the present invention and / or its suppository base and / or excipients may promote the growth of beneficial vaginal microorganisms.

[0017] Suppository bases are classified as oily (i.e., fatty) bases and water-soluble / water-miscible bases. Oily (i.e., fatty) bases include, but are not limited to, cocoa butter (i.e., cocoa butter), and C8-C9 20Fatty acid triglycerides, monoglycerides, and diglycerides, as well as mixtures thereof, are included. Examples of fatty acids include, but are not limited to, capric acid, caprylic acid, eicosenoic acid, stearic acid, lauric acid, myristic acid, oleic acid, palmitic acid, ricinoleic acid, and derivatives thereof. In some embodiments, the fatty base may be prepared from its natural source (e.g., coconut oil, palm oil, etc.) and / or may be mixed with various additives. Examples of trade names for fatty bases include, but are not limited to, Suppocire™, Ovucire™, Japocire™, Witepsol™, Massa estarinum™, Wecobee™, Fattibase™, Dehydag™, Hydrokote™, and Novata™.

[0018] Water-soluble / water-miscible bases include, but are not limited to, gelatin (e.g., glycerinated gelatin), polyethylene glycol (PEG), and glycerolized glycerin. In some embodiments, the suppository base of the present invention may include both a fatty base and a water-soluble / water-miscible base.

[0019] In some embodiments, the suppository base may be present in the vaginal suppository of the present invention in an amount of about 0.1% to about 99.9% by weight of the suppository. In some embodiments, the suppository base may be present in an amount of about 0.1% to about 1%, about 0.1% to about 5%, about 0.1% to about 10%, about 0.1% to about 20%, about 1% to about 10%, about 1% to about 20%, about 20% to about 30%, about 30% to about 40%, about 40% to about 50%, about 5% by weight of the suppository. In some embodiments, the suppository base may be present in an amount of 0% to about 60% by weight, about 60% to about 70% by weight, about 70% to about 99.9% by weight, about 70% to about 95% by weight, about 70% to about 90% by weight, about 70% to about 85% by weight, about 70% to about 80% by weight, about 70% to about 75% by weight, about 80% to about 90% by weight, or about 90% to about 99.9% by weight. In some embodiments, the suppository base may be present in an amount of 70%, 75%, 80%, 85%, 90%, or 95% or more by weight of the vaginal suppository.For example, in some embodiments, the suppository base comprises about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 24%, about 26%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91% by weight of the suppository. About 23% by weight, about 24% by weight, about 25% by weight, about 26% by weight, about 27% by weight, about 28% by weight, about 29% by weight, about 30% by weight, about 31% by weight, about 32% by weight, about 33% by weight, about 34% by weight, about 35% by weight, about 36 Weight%, about 37% by weight, about 38% by weight, about 39% by weight, about 40% by weight, about 41% by weight, about 42% by weight, about 43% by weight, about 44% by weight, about 45% by weight, about 46% by weight, about 47% by weight, about 48% by weight, about 49% by weight, About 50% by weight, about 51% by weight, about 52% by weight, about 53% by weight, about 54% by weight, about 55% by weight, about 56% by weight, about 57% by weight, about 58% by weight, about 59% by weight, about 60% by weight, about 61% by weight, about 62% by weight, about 63 Weight%, about 64% by weight, about 65% by weight, about 66% by weight, about 67% by weight, about 68% by weight, about 69% by weight, about 70% by weight, about 71% by weight, about 72% by weight, about 73% by weight, about 74% by weight, about 75% by weight, about 76% by weight, It may be present in the vaginal suppositories of the present invention in an amount of about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 99.9% by weight.

[0020] In some embodiments, the suppository base in the suppositories of the present invention can be hydrophobic (e.g., completely hydrophobic). In some embodiments, the suppository base in the suppositories of the present invention can be hydrophilic (e.g., PEG-based suppository base and / or glycerol-gelatin). In some embodiments, the suppository base can have a low acid value, which can reduce and / or prevent premature release of nitric oxide (e.g., during production and / or storage). For example, the suppository base can have an acid value of less than about 3 mg KOH / g, e.g., less than about 2.5 mg KOH / g, less than about 2 mg KOH / g, less than about 1.5 mg KOH / g, less than about 1 mg KOH / g, less than about 0.5 mg KOH / g, or less than about 0.2 mg KOH. In some embodiments, the suppository base can be soluble or dispersible in water and / or melt at body temperature.

[0021] In some embodiments, the buffering agent may be present in the suppository of the present invention in an amount of about 0.1% to about 30% by weight of the suppository. For example, in some embodiments, the buffering agent may be present in the suppository of the present invention in an amount of about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, or about 30% by weight of the suppository. In some embodiments, two or more buffering agents may be present in the vaginal suppository of the present invention, and each of the two or more buffering agents may be present in the vaginal suppository of the present invention in an amount of about 0.1% to about 15% by weight of the vaginal suppository (e.g., about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15% by weight of the vaginal suppository).

[0022] Exemplary buffering agents include, but are not limited to, potassium dihydrogen phosphate, phosphoric acid, citric acid, acetic acid, lactic acid, boric acid, succinic acid, malic acid, sodium citrate dihydrate, and any combination thereof. In some embodiments, the buffering agent (e.g., acetate buffer) may have a strong buffering capacity at the physiological pH of the vagina. In some embodiments, the vaginal suppository and / or the buffering agent present in the vaginal suppository may have a buffering capacity of about 50, about 100, about 200, or about 300 μmol / g to about 400, about 500, about 600, or about 700 μmol / g. In some embodiments, the vaginal suppository and / or the buffering agent present in the vaginal suppository have a buffering capacity of about 50, about 100, about 150, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 550, about 600, about 650, or about 700 μmol / g.

[0023] In some embodiments, the preservative may be present in the suppository of the present invention in an amount of about 0.1% to about 2% by weight of the suppository, for example, but not limited to, about 0.1% to about 1% by weight, or about 0.1% to about 2% by weight of the suppository. In some embodiments, the preservative is present in the suppository in an amount of about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, or about 2% by weight of the suppository.

[0024] Exemplary preservatives that may be present in vaginal suppositories include, but are not limited to, sorbic acid, benzoic acid, methyl-paraben, propyl-paraben, methylchloroisothiazolinone, methylisothiazolinone, diazolidinyl urea, chlorobutanol, triclosan, benzethonium chloride, p-hydroxybenzoic acid esters, chlorhexidine, digluconate, hexadecyltrimethylammonium bromide, alcohols, benzalkonium chloride, boric acid, bronopol, butylparaben, calcium butylene acetate, calcium chloride, calcium lactate, carbon dioxide, cationic and bentonite, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, methylparaben, methylchloro ...chlorobutanol, methylparaben, methylchloroisothiazolinone, diazolidinyl urea, chlorobutanol, triclosan, benzethonium chloride, p-hydroxybenzoic acid esters, chlorhexidine, chlorobutanol, methylparaben, methylparaben, methylparaben, methylparaben, methylparaben, methylparab ethanol, chlorocresol, chloroxylenol, citric acid monohydrate, cresol, dimethyl ether, ethylparaben, glycerin, hexetidine, imidurea, isopropyl alcohol, lactic acid, monothioglycerol, pentetic acid, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, potassium benzoate, potassium metabisulfite, potassium sorbate, propionic acid, propyl gallate, propylene glycol, sodium acetate, sodium benzoate, sodium borate, sodium lactate, sodium sulfite, sodium propionate, sodium metabisulfite, xylitol, sulfur dioxide, carbon dioxide, and any combination thereof.

[0025] In some embodiments, the solvent may be present in an amount of about 0.1% to about 99.8% by weight of the suppository, for example, but not limited to, about 0.1% to about 1% by weight, about 0.1% to about 5% by weight, about 0.1% to about 10% by weight, about 0.1% to about 20% by weight, about 1% to about 10% by weight, about 1% to about 20% by weight, about 20% to about 30% by weight, about 30% to about 40% by weight, about 40% to about 50% by weight, about 50% to about 60% by weight, about 60% to about 70% by weight, about 70% to about 80% by weight, about 80% to about 90% by weight, or about 90% to about 99.8% by weight of the suppository.In some embodiments, the solvent comprises about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23% by weight of the vaginal suppository. Amount%, about 24% by weight, about 25% by weight, about 26% by weight, about 27% by weight, about 28% by weight, about 29% by weight, about 30% by weight, about 31% by weight, about 32% by weight, about 33% by weight, about 34% by weight, about 35% by weight, about 36% by weight, About 37% by weight, about 38% by weight, about 39% by weight, about 40% by weight, about 41% by weight, about 42% by weight, about 43% by weight, about 44% by weight, about 45% by weight, about 46% by weight, about 47% by weight, about 48% by weight, about 49% by weight, about 50 Weight%, about 51% by weight, about 52% by weight, about 53% by weight, about 54% by weight, about 55% by weight, about 56% by weight, about 57% by weight, about 58% by weight, about 59% by weight, about 60% by weight, about 61% by weight, about 62% by weight, about 63% by weight , about 64% by weight, about 65% by weight, about 66% by weight, about 67% by weight, about 68% by weight, about 69% by weight, about 70% by weight, about 71% by weight, about 72% by weight, about 73% by weight, about 74% by weight, about 75% by weight, about 76% by weight, about 7 It may be present in the vaginal suppositories of the present invention in an amount of about 7%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 99.8% by weight.

[0026] Exemplary solvents include, but are not limited to, acetone, methyl alcohol, ethanol, isopropanol, butyl alcohol, ethyl acetate, dimethyl isosorbide, propylene glycol, glycerin, ethylene glycol, polyethylene glycol, diethylene glycol monoethyl ether, water (e.g., purified and / or sterile water), and mixtures thereof. In some embodiments, the solvent in the vaginal suppositories of the present invention may be glycerin.

[0027] In some embodiments, a lubricant may be present in the vaginal suppository of the present invention. The lubricant may help reduce friction between the surface of the subject's vagina and the vaginal suppository during and / or after administration of the suppository to the subject's vagina. In some embodiments, the lubricant may be present in the vaginal suppository of the present invention in an amount of about 1% to about 10% by weight of the suppository. For example, in some embodiments, the lubricant may be present in the vaginal suppository of the present invention in an amount of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10% by weight of the suppository.

[0028] Exemplary lubricants include, but are not limited to, magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oil, Sterotex, polyoxyethylene monostearate, talc, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, and mineral oil (e.g., light mineral oil), or combinations thereof. In some embodiments, lubricants can enhance and / or improve the manufacturing of suppositories.

[0029] In some embodiments, mineral oil and / or hard wax may be present in the suppository of the present invention and may improve handling during manufacturing. In some embodiments, mineral oil may be present in the suppository of the present invention in an amount of about 1% to about 10% or about 1% to about 20% by weight of the suppository. For example, in some embodiments, mineral oil may be present in the suppository of the present invention in an amount of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% by weight of the suppository. In some embodiments, one or more (e.g., 1, 2, 3, 4) hard waxes may be present in the suppository of the present invention in an amount of about 1% to about 10% or about 1% to about 20% by weight of the suppository. For example, in some embodiments, one or more hard waxes may be present in the suppository of the present invention in an amount of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% by weight of the suppository.

[0030] In some embodiments, the vaginal suppositories of the present invention comprise excipients, prebiotics, probiotics, and / or synbiotics, which may enhance tolerance and / or comply with FDA guidance regarding vaginal microbicides. In some embodiments, the excipients, prebiotics, probiotics, and / or synbiotics may be present in the vaginal suppositories of the present invention in an amount sufficient to enhance tolerance, provide a therapeutic effect, and / or enhance the health and / or growth of the vaginal microbiota (e.g., normal growth and / or numbers of the microbiota).

[0031] In some embodiments, the NO-releasing API may be present in the suppository of the present invention in an amount of about 0.1% to about 70% by weight of the suppository. For example, in some embodiments, the NO-releasing API may be present in the suppository of the present invention in an amount of about 0.1% to about 10%, about 0.1% to about 20%, about 20% to about 30%, about 30% to about 40%, about 40% to about 50%, about 50% to about 60%, or about 60% to about 70% by weight of the suppository. In some embodiments, the NO-releasing API may be present in the vaginal suppositories of the present invention in an amount of about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, or about 70% by weight of the vaginal suppository.

[0032] As used herein, "nitric oxide-releasing pharmaceutical ingredient" and "NO-releasing API" refer to a compound or other composition that provides nitric oxide to the skin (e.g., mucosa) and / or tissue of a subject, but is not gaseous nitric oxide. In some embodiments, the NO-releasing API is also not an acidified nitrite. In some embodiments, the NO-releasing API includes a nitric oxide-releasing compound, hereinafter referred to as an "NO-releasing compound." The NO-releasing compound includes at least one NO donor, which is a functional group that can release nitric oxide under certain conditions.

[0033] Any suitable NO-releasing compound may be used. In some embodiments, the NO-releasing compound includes a small molecule compound containing an NO-donating group. As used herein, "small molecule compound" is defined as a compound having a molecular weight of less than 500 daltons and includes organic and / or inorganic small molecule compounds. In some embodiments, the NO-releasing compound includes a polymer containing an NO-donating group. "Polymer" is defined herein as any compound having a molecular weight of 500 daltons or greater. Any suitable polymer may be used, including crosslinked or non-crosslinked polymers, dendrimers, metal compounds, organometallic compounds, inorganic compounds, and other polymeric scaffolds. In some embodiments, the polymer has a nominal diameter of about 0.1 nm to about 100 μm and may include aggregates of two or more polymers, whereby the polymer structure is further modified with an NO-donating group.

[0034] In some embodiments, the NO-releasing compound comprises a diazeniumdiolate functional group as the NO donor. The diazeniumdiolate functional group can generate nitric oxide under certain conditions, for example, when exposed to water. As another example, in some embodiments, the NO-releasing compound comprises a nitrosothiol functional group as the NO donor. The NO donor can generate nitric oxide under certain conditions, for example, when exposed to light. Examples of other NO-releasing groups include nitrosamine, hydroxylnitrosamine, hydroxylamine, and hydroxyurea. Any suitable combination of NO donor and / or NO-releasing compound can also be used in the vaginal suppositories described herein. In addition, the NO donor can be incorporated into or onto the small molecule or polymer through covalent and / or non-covalent interactions.

[0035] The NO-releasing polymer may be in the form of NO-releasing particles, such as those described in U.S. Pat. Nos. 8,282,967, 8,962,029, or 8,956,658, the disclosures of which are incorporated herein by reference in their entireties. Other non-limiting examples of NO-releasing compounds include NO-releasing zeolites described in U.S. Patent Application Publication Nos. 2006 / 0269620 or 2010 / 0331968; NO-releasing metal-organic frameworks (MOFs) described in U.S. Patent Application Publication Nos. 2010 / 0239512 or 2011 / 0052650; NO-releasing multiple donor compounds described in International Application No. PCT / US2012 / 052350, entitled "Tunable Nitric Oxide-Releasing Macromolecules Having Multiple Nitric Oxide Donor Structures"; NO-releasing dendrimers or metal structures described in U.S. Patent Application Publication No. 2009 / 0214618; nitric oxide-releasing coatings described in U.S. Patent Application Publication No. 2011 / 0086234; and compounds described in U.S. Patent Application Publication No. 2010 / 0098733. The disclosures of each of the references in this paragraph are incorporated herein by reference in their entirety. Additionally, NO-releasing polymers can be made as described in International Application No. PCT / US2012 / 022048, entitled "Temperature Controlled Sol-Gel Co-Condensation," filed January 20, 2012, the disclosure of which is incorporated herein by reference in its entirety.

[0036] As an example, in some embodiments of the present invention, the nitric oxide-releasing pharmaceutical ingredient can include NO-loaded precipitated silica. The NO-loaded precipitated silica can be formed from a silane monomer modified with a nitric oxide donor to a co-condensed siloxane network. In one embodiment of the present invention, the nitric oxide donor can be an N-diazeniumdiolate. In some embodiments of the present invention, the nitric oxide-releasing pharmaceutical ingredient can comprise, consist essentially of, or consist of a co-condensed siloxane network containing a diazeniumdiolate (e.g., an N-diazeniumdiolate).

[0037] In some embodiments, the nitric oxide donor can be formed from an aminoalkoxysilane by a pre-charging method, and the co-condensed siloxane network can be synthesized from the condensation of a silane mixture containing an alkoxysilane and the aminoalkoxysilane to form a co-condensed siloxane network modified with a nitric oxide donor. As used herein, the "pre-charging method" means that the alkoxysilane is "pretreated" or "precharged" with nitric oxide before co-condensation with the aminoalkoxysilane. In some embodiments, pre-charging with nitric oxide can be achieved by chemical methods. In another embodiment, the "pre-charging" method can be used to create co-condensed siloxane networks and materials that are more densely functionalized with NO donors. In some embodiments of the present invention, the nitric oxide-releasing pharmaceutical ingredient may comprise, consist essentially of, or consist of a co-condensed silica network synthesized from the condensation of a silane mixture comprising an alkoxysilane and at least one aminoalkoxysilane having a diazeniumdiolate (e.g., N-diazeniumdiolate) substituted amine.

[0038] The co-condensed siloxane network can be silica particles having a uniform size, a collection of silica particles having various sizes, amorphous silica, fumed silica, nanocrystalline silica, ceramic silica, colloidal silica, silica coating, silica film, organically modified silica, mesoporous silica, silica gel, bioactive glass, or any suitable form or state of silica.

[0039] In some embodiments, the alkoxysilane is a tetraalkoxysilane having the formula Si(OR)4, where R is an alkyl group. The R groups can be the same or different. In some embodiments, the tetraalkoxysilane is selected as tetramethyl orthosilicate (TMOS) or tetraethyl orthosilicate (TEOS). In some embodiments, the aminoalkoxysilane has the formula R"-(NH-R') n -Si(OR)3, where R is alkyl, R' is alkylene, branched alkylene, or aralkylene, n is 1 or 2, and R" is selected from the group consisting of alkyl, cycloalkyl, aryl, and alkylamine.

[0040] In some embodiments, the aminoalkoxysilane can be selected from N-(6-aminohexyl)aminopropyltrimethoxysilane (AHAP3); N-(2-aminoethyl)-3-aminopropyltrimethoxysilane (AEAP3); (3-trimethoxysilylpropyl)diethylenetriamine (DET3); (aminoethylaminomethyl)phenethyltrimethoxysilane (AEMP3); [3-(methylamino)propyl]trimethoxysilane (MAP3); N-butylaminopropyltrimethoxysilane (n-BAP3); t-butylaminopropyltrimethoxysilane (t-BAP3); N-ethylaminoisobutyltrimethoxysilane (EAiB3); N-phenylaminopropyltrimethoxysilane (PAP3); and N-cyclohexylaminopropyltrimethoxysilane (cHAP3).

[0041] In some embodiments, the aminoalkoxysilane has the formula NH[R'-Si(OR)], where R is alkyl and R' is alkylene. In some embodiments, the aminoalkoxysilane can be selected from bis(3-triethoxysilylpropyl)amine, bis-[3-(trimethoxysilyl)propyl]amine, and bis-[(3-trimethoxysilyl)propyl]ethylenediamine.

[0042] In some embodiments, the aminoalkoxysilane is precharged for NO release, and the amino group is substituted with a diazeniumdiolate, as described herein above. Thus, in some embodiments, the aminoalkoxysilane has the formula R″—N(NONO-X + )-R'-Si(OR)3, where R is alkyl, R' is alkylene or aralkylene, R" is alkyl or alkylamine, and X + Na + , K. + and Li + is a cation selected from the group consisting of:

[0043] The composition of the siloxane network (e.g., the amount or chemical composition of the aminoalkoxysilane) and nitric oxide charging conditions (e.g., solvent and base) can be varied to optimize the amount and duration of nitric oxide release. Thus, in some embodiments, the composition of the silica particles can be modified to adjust the half-life of NO release from the silica particles.

[0044] In another embodiment, the amino group of the aminoalkoxysilane is substituted with a diazeniumdiolate, and the aminoalkoxysilane is R″—N(NONO-X + )-R'-Si(OR)3, where R is alkyl, R' is alkylene or aralkylene, R" is alkyl or alkylamine, and X + Na + and K. + is a cation selected from the group consisting of:

[0045] In some embodiments, the NO-releasing API can comprise a co-condensed silica network comprising diazeniumdiolated aminoethylaminopropyltrimethoxysilane (AEAP3) and tetramethyl orthosilicate (TMOS), and / or a co-condensed silica network comprising diazeniumdiolated aminoethylaminopropyltrimethoxysilane (AEAP3) and tetraethyl orthosilicate (TEOS). In some embodiments, the NO-releasing API can comprise a co-condensed silica network comprising diazeniumdiolated methylaminopropyltrimethoxysilane (MAP3) and tetramethyl orthosilicate (TMOS), and / or a co-condensed silica network comprising diazeniumdiolated methylaminopropyltrimethoxysilane (MAP3) and tetraethyl orthosilicate (TEOS). In some embodiments, the NO-releasing API can comprise a co-condensed silica network comprising diazeniumdiolated methylaminopropyltrimethoxysilane (MAP3), ethylaminoisobutylsiloxane (EAIB3), and tetraethyl orthosilicate (TEOS). In some embodiments, the NO-releasing API can be ethylaminoisobutylsiloxane / methylaminopropylsiloxane-copolysiloxane (EAIB3:MAP3-NONOate / TEOS). In some embodiments, the NO-releasing API can comprise an amorphous polymer.

[0046] In some embodiments of the present invention, the particle size of the NO-releasing API can be about 20 nm to about 20 μm, or any range therein, such as, but not limited to, about 100 nm to about 20 μm or about 1 μm to about 20 μm. The particle size can be adjusted to minimize or prevent toxicity and / or penetration into blood vessels through the epidermis (or compromised dermis). In certain embodiments, the particle size is distributed about an average particle size of less than 20 μm or any range therein, which may allow the particle to enter the ovarian follicle. In some embodiments, the NO-releasing API can have a particle size distributed about an average particle size of about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, about 2, or about 1 μm. In further embodiments, the NO-releasing API can have a particle size distribution about an average particle size of less than 10 μm or any range therein, such as, but not limited to, about 2 μm to about 10 μm or about 4 μm to about 8 μm. In other embodiments, the particle size distribution can be greater than 20 μm or any range therein, which can prevent the particles from entering the follicle. In further embodiments, a mixture of particles having average particle sizes distributed about two or more average particle sizes can be provided. The NO-releasing API can be micronized (e.g., ball and / or jet milled). Methods for achieving the desired particle size and / or micronization include, but are not limited to, those described in U.S. Patent Application Publication No. 2013 / 0310533, the entire contents of which are incorporated herein by reference.

[0047] In some embodiments, the NO-releasing API can have a low charge. In some embodiments, the charge of the NO-releasing API can be controlled and / or regulated.

[0048] The vaginal suppository of the present invention may comprise an NO-releasing API and may store and / or release nitric oxide in an amount of about 0.01% to about 10% by weight of the vaginal suppository, for example, but not limited to, about 0.15% to about 2% by weight, about 0.15% to about 1% by weight, about 0.3% to about 1.2% by weight, about 0.15% to about 6% by weight, about 1% to about 10% by weight, about 3% to about 6% by weight, or about 1% to about 5% by weight of the vaginal suppository. In some embodiments, the vaginal suppositories of the present invention may comprise a nitric oxide-releasing active pharmaceutical agent, and may be present in an amount of about 0.01%, about 0.05%, about 0.1%, about 0.15%, about 0.3%, about 0.6%, about 0.9%, about 1%, about 1.25%, about 1.5%, about 1.75%, about 2%, about 2.25%, about 2.5%, about 2.75%, about 3%, about 3.25%, about 3.5%, about 3.75%, about 4%, about 4.25% by weight of the vaginal suppository. The composition may store and / or release nitric oxide in an amount of about 4.5%, about 4.75%, about 5%, about 5.25%, about 5.5%, about 5.75%, about 6%, about 6.25%, about 6.5%, about 6.75%, about 7%, about 7.25%, about 7.5%, about 7.75%, about 8%, about 8.25%, about 8.5%, about 8.75%, about 9%, about 9.25%, about 9.5%, about 9.75%, or about 10% by weight. The amount of released nitric oxide may be determined using a real-time in vitro release test. In some embodiments, nitric oxide release may be determined using a chemiluminescent nitric oxide analyzer.

[0049] The vaginal suppository of the present invention may release nitric oxide in an acidic environment. Upon administration (e.g., insertion and / or placement) of the vaginal suppository of the present invention to a subject, the pH of the subject's vagina may be maintained at less than 7. In some embodiments, upon administration of the vaginal suppository of the present invention to a subject, the pH of the subject's vagina may be maintained at less than about 6, 5, 4, or 3. In some embodiments, upon administration of the vaginal suppository of the present invention to a subject, the pH of the subject's vagina may be about 3.5 to about 4.8. In some embodiments, administration of the vaginal suppository of the present invention to a subject may not change the pH of the subject's vagina by more than 2 pH units. For example, administration of the vaginal suppository of the present invention to a subject may change the pH of the subject's vagina by 2 pH units or less, such as about 1.5, about 1, about 0.5, or about 0 pH units.

[0050] In some embodiments, upon administration of a vaginal suppository of the present invention to a subject, the subject's vagina can have a net alkalinity within a physiologically acceptable range and / or a net alkalinity equivalent to the physiological net alkalinity in the absence of the vaginal suppository of the present invention.

[0051] The vaginal suppositories of the present invention may have no or reduced side effects and / or toxicity. In some embodiments, the vaginal suppositories of the present invention do not have and / or cause reproductive toxicity, more than mild vaginal irritation, and / or chromosomal abnormalities.

[0052] As used herein, the term "shelf life" refers to the length of time that the vaginal suppository of the present invention maintains its ability to release a therapeutically effective amount of a therapeutic agent, such as, but not limited to, nitric oxide, in an unopened package stored under recommended storage conditions. The shelf life may be indicated, for example, by the "use by" or "recommended use by" date of the vaginal suppository, the manufacturer's expiration date of the vaginal suppository, and / or the actual characteristics of the vaginal suppository after a specified period of time. Therefore, as used herein, the term "shelf life" should be interpreted to encompass both the "actual" shelf life of the vaginal suppository and the "expected" shelf life of the vaginal suppository, unless otherwise stated. As those skilled in the art will recognize, the rate of release of nitric oxide in a vaginal suppository in its packaged and / or stored state may differ (i.e., may be faster or slower) from the rate of release of nitric oxide when the vaginal suppository is in use (e.g., administered to a subject). In some embodiments, the rate of release of nitric oxide from a vaginal suppository of the present invention may be more rapid when the suppository is in use compared to the rate of release of nitric oxide when the suppository containing an API is packaged and / or stored.

[0053] In some embodiments, shelf life can be determined by extrapolating data at accelerated temperatures, such as by using the Arrhenius equation. In some embodiments, shelf life can be determined using linear regression analysis, such as when the kinetics of API degradation are not temperature dependent. In some embodiments, shelf life can be assessed and / or determined by measuring the API (e.g., an NO-releasing API), such as by using high pressure liquid chromatography.

[0054] In some embodiments, the shelf life of the vaginal suppository is the time during which the vaginal suppository, when packaged, maintains its ability to release at least 50% of its initial releasable amount of nitric oxide. In some embodiments, the shelf life of the vaginal suppository is the time during which the vaginal suppository, when packaged, maintains its ability to release about 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% of its initial releasable amount of nitric oxide. In some embodiments, the shelf life of the vaginal suppository is the time during which the vaginal suppository maintains its ability to release a therapeutically effective amount of nitric oxide for a desired period of time. In some embodiments, the recommended storage conditions are room temperature. In some embodiments, the recommended storage conditions are refrigerated storage conditions, in which the refrigerated storage conditions are about 1°C to about 12°C or about 2°C to about 8°C. In some embodiments, the packaged vaginal suppositories may have a shelf life of at least about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, or about 24 months or more, or any range and / or individual value therein. In some embodiments, the vaginal suppositories of the present invention may have a shelf life of at least about 2 years when stored at 25°C / 60% relative humidity (RH) and / or at least about 6 months when stored at 40°C / 75% RH. In some embodiments, the vaginal suppositories of the present invention may have a shelf life of at least about 2 years when stored at a temperature of about 2°C to about 8°C and / or at least about 6 months when stored at 25°C / 60% RH.

[0055] Some embodiments may provide a packaged vaginal suppository of the present invention having a useful life of at least about 7 days after opening the vaginal suppository. In some embodiments, the useful life is at least about 30 days, at least about 60 days, at least about 90 days, or at least about 1, about 2, about 3, about 4, about 5, about 6, about 8, or about 9 months. In further embodiments, the packaged vaginal suppository may have a useful life of at least about 60 days to at least about 730 days. As used herein, the term "useful life" refers to the length of time that the vaginal suppository maintains its ability to release a therapeutically effective amount of nitric oxide from an opened packaged vaginal suppository when applied as recommended and stored under recommended storage conditions. The useful life may be determined, for example, by the manufacturer's recommended time for disposing of the vaginal suppository after opening or by measuring the properties of the vaginal suppository after opening.

[0056] Therefore, as used herein, the term "useful period" should be interpreted to encompass both the "actual" useful period of the vaginal suppository and the "projected" useful period of the vaginal suppository, unless otherwise stated. In some embodiments, the useful period of the vaginal suppository is the time during which the vaginal suppository, when opened, maintains the ability to release at least 50% of the initial amount of nitric oxide that it can release. In further embodiments, the useful period of the vaginal suppository is the time during which the vaginal suppository, when opened, maintains the ability to release at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% of the initial amount of nitric oxide that it can release. In some embodiments, the recommended storage conditions after opening are room temperature, and in some embodiments, the recommended storage conditions after opening are refrigerated conditions.

[0057] The rate of nitric oxide release from the vaginal suppositories of the present invention can be controlled and / or regulated by the availability of protons in the surrounding environment. In some embodiments, the vaginal suppositories of the present invention can have an NO release rate, manner, and / or amount described in International Application No. PCT / US2015 / 039908 and / or International Application No. PCT / US2016 / 012668, the entire contents of each of which are incorporated herein by reference. In some embodiments, the vaginal suppositories of the present invention can release nitric oxide at a release rate suitable for allowing and / or achieving penetration of NO into and / or onto the tissues of the vagina upon administration, and can be physiologically acceptable. In some embodiments, the vaginal suppositories of the present invention can release nitric oxide at a release rate suitable for allowing and / or achieving penetration of NO into and / or onto the cervical tissues of a subject upon administration of the vaginal suppository to the vagina of the subject.

[0058] In some embodiments, the vaginal suppository of the present invention may be a monophasic system (i.e., a single unit dosage form). A monophasic system may have a single layer, or multiple layers (e.g., a buffer in an outer layer and an API in an inner layer and / or core) may be present in the single unit dosage form. In the monophasic system, the vaginal suppository of the present invention may release nitric oxide upon interaction and / or contact with the physiological pH of the vagina. In some embodiments, the API and proton source may be combined in the monophasic system of the present invention so that they interact only after administration of the vaginal suppository into the vagina of a subject. In some embodiments, the vaginal suppository of the present invention may be a biphasic system. In the biphasic system, an activator separate from the vaginal suppository of the present invention (e.g., water or a hydrogel-based activator) may be used to initiate the release of nitric oxide from the vaginal suppository.

[0059] In some embodiments, upon administration of a vaginal suppository of the present invention to a subject, the vaginal suppository may melt and / or form a film or coating on the surface of the subject's vagina. In some embodiments, the vaginal suppository provides a film or coating on at least about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 90%, about 95%, or about 100% of the subject's vaginal surface. In some embodiments, the vaginal suppository provides a film or coating on a portion (e.g., 25%, 50%, 75%) or all (i.e., 100%) of the diseased area of ​​the subject's vaginal surface. In some embodiments, upon administration of the vaginal suppository of the present invention to a subject, the vaginal suppository provides a coating or coverage of at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 90%, about 95%, or about 100% of the subject's cervical tissue. In some embodiments, the vaginal suppository of the present invention may have an appropriate osmolality. In some embodiments, the vaginal suppository of the present invention may have an osmolality of about 10 mOsm / kg to about 8000 mOsm / kg or about 250 mOsm / kg to about 400 mOsm / kg.In some embodiments, the vaginal suppository of the present invention has a blood glucose concentration of about 10 mOsm / kg to about 100 mOsm / kg, about 100 mOsm / kg to about 200 mOsm / kg, about 200 mOsm / kg to about 300 mOsm / kg, about 300 mOsm / kg to about 400 mOsm / kg, about 400 mOsm / kg to about 500 mOsm / kg, about 500 mOsm / kg to about 600 mOsm / kg, about 600 mOsm / kg to about 700 mOsm / kg, about 700 mOsm / kg to about 800 mOsm / kg, or about 800 mOsm / kg to about 900 mOsm / kg. mOsm / kg, about 900 mOsm / kg to about 1000 mOsm / kg, about 1000 mOsm / kg to about 2000 mOsm / kg, about 2000 mOsm / kg to about 3000 mOsm / kg, about 3000 mOsm / kg to about 4000 mOsm / kg, about 4000 mOsm / kg to about 5000 mOsm / kg, about 5000 mOsm / kg to about 6000 mOsm / kg, about 6000 mOsm / kg to about 7000 mOsm / kg, or about 7000 mOsm / kg to about 8000 mOsm / kg. For example, vaginal suppositories of the present invention can have an osmolality of about 10, about 50, about 100, about 150, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 550, about 600, about 650, about 700, about 750, about 800, about 850, about 900, about 950, about 1000, about 2000, about 3000, about 4000, about 5000, about 6000, about 7000, or about 8000 mOsm / kg.

[0060] In some embodiments, the vaginal suppository of the present invention may have a volume of about 0.5 mL to about 5 mL. For example, the vaginal suppository of the present invention may have a volume of about 0.5 mL, about 1 mL, about 1.5 mL, about 2 mL, about 2.5 mL, about 3 mL, about 3.5 mL, about 4 mL, about 4.5 mL, or about 5 mL.

[0061] In some embodiments, the vaginal suppositories of the present invention may adhere to and / or be mucoadhesive to the surface of the vagina. In some embodiments, the vaginal suppositories of the present invention may have a mean residence time appropriate for the activity, treatment, and / or administration regimen. In some embodiments, the vaginal suppositories of the present invention may have a mean residence time suitable for providing a therapeutic effect to the subject. In some embodiments, the vaginal suppositories of the present invention may have a mean residence time related to the duration of administration of a therapeutically effective amount of the API and / or NO to the subject. In some embodiments, the vaginal suppositories of the present invention may have a mean residence time that is at least equivalent to the duration of time the vaginal suppository releases NO.

[0062] In some embodiments, the suppository of the present invention may be an anhydrous suppository. As used herein, "anhydrous" means that there is no direct addition of water to the suppository when it is prepared. However, those skilled in the art will recognize that water may be physically and / or chemically absorbed by the suppository and / or by one or more components of the suppository at any time during its preparation, storage, and / or use (i.e., indirect addition of water to the suppository). In some embodiments, the term "anhydrous" means that the suppository has a water content of less than 5% by weight of the suppository, or any range and / or individual value therein. The suppository may have a water content of less than 5%, less than 4.5%, less than 4%, less than 3.5%, less than 3%, less than 2.5%, less than 2%, less than 1.5%, less than 1%, or less than 0.5%, or any range therein. Water content may be measured by methods known to those skilled in the art, such as, but not limited to, Karl Fischer titration.

[0063] According to some embodiments of the present invention, provided herein are methods for treating and / or preventing viral, bacterial, protozoan, and / or fungal infections in and / or in a subject. In some embodiments, the vaginal suppositories and / or methods of the present invention may treat and / or prevent viral, bacterial, protozoan, and / or fungal infections in and / or in a subject. In some embodiments, the vaginal suppositories of the present invention may be antimicrobial (e.g., antiviral, antibacterial, and / or antifungal).

[0064] According to some embodiments of the present invention, methods for treating and / or preventing an infection (e.g., a viral infection) are provided herein. The methods for treating and / or preventing an infection (e.g., a viral infection) may include administering a vaginal suppository of the present invention to a subject's vagina, thereby treating and / or preventing the infection in the subject. In some embodiments, the vaginal suppository may be administered, such as by inserting and / or placing the vaginal suppository into the subject's vagina. In some embodiments, the methods of the present invention may suppress and / or inhibit viral replication and / or enhance a subject's local immune response. In some embodiments, administration of the vaginal suppository may achieve local and / or transdermal delivery of nitric oxide (NO) to the subject. In some embodiments, the methods of the present invention may achieve targeted delivery of NO to the subject's vagina or a portion thereof, and / or achieve local or systemic delivery of NO to the subject's surrounding tissues and / or organs. In some embodiments, administering a vaginal suppository of the present invention may administer NO to a subject's tissue and / or through the tissue to a localized region.

[0065] Exemplary viral infections include, but are not limited to, viral infections caused by cytomegalovirus (CMV), Epstein-Barr virus, herpes simplex virus (HSV1+2), shingles, human herpes virus 6 (HHV-6), human herpes virus 8 (HHV-8), papilloma virus, and / or molluscum contagiosum. In some embodiments, the viral infection can be caused by a papilloma virus, such as a human papilloma virus. The human papilloma virus (HPV) can be HPV types 1, 2, 3, 4, 6, 10, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and / or 59. In some embodiments, the viral infection can be caused by a herpes simplex virus, such as herpes simplex type 1 and / or herpes simplex type 2. In some embodiments, the viral infection can infect vaginal and / or cervical tissue of the subject. In certain embodiments, the virus can be a human virus.

[0066] In some embodiments, the vaginal suppositories of the present invention can be used to treat and / or prevent high-risk HPV-mediated cervical intraepithelial neoplasia (CIN). In some embodiments, the vaginal suppositories and / or methods of the present invention produce and / or provide a negative PCR result for HPV using a cervical brush after administration of the vaginal suppository and / or treatment with the vaginal suppository.

[0067] As used herein, "treat," "treating," or "treatment of" (and grammatical conjugations thereof) refers to any type of treatment that confers benefit to a subject and can mean that the severity of the subject's condition is reduced or at least partially improved or ameliorated, and / or some alleviation, relief, or reduction of at least one clinical symptom associated with the condition (e.g., a viral infection) is achieved, and / or there is a delay in the progression of the condition. In some embodiments, the severity of a condition, such as a viral infection (e.g., a viral infection caused by human papillomavirus), can be reduced in a subject compared to the severity of the condition in the absence of a method of the invention. In certain embodiments, a method of the invention treats a viral infection in a subject, such as a viral infection affecting the vagina of the subject. In some embodiments, a method of the invention can treat a viral infection by eliminating and / or reducing the size and / or appearance of at least one clinical symptom (e.g., a benign lesion) associated with the viral infection. In some embodiments, the methods of the present invention may treat a viral infection by eliminating at least one clinical symptom (e.g., a benign lesion) associated with the viral infection for a given period of time (e.g., 1 day, 2 days, 3 days, 4 days, 5 days, or 6 days, or 1 week, 2 weeks, 3 weeks, 4 weeks or more, etc.).

[0068] In some embodiments, the vaginal suppositories of the present invention are administered in a therapeutically effective amount. The terms "therapeutically effective amount" and "therapeutically effective amount" are used interchangeably herein and refer to an amount sufficient to treat (as defined herein) a subject. One of ordinary skill in the art will understand that a therapeutic effect need not be complete or curative, as long as some benefit is provided to the subject. In some embodiments, a therapeutically effective amount of the vaginal suppository of the present invention can be administered and can include administering a therapeutically effective amount of a nitric oxide-releasing pharmaceutical ingredient. In some embodiments, a therapeutically effective amount of nitric oxide can be administered and / or applied in the methods of the present invention. In some embodiments, the methods of the present invention are carried out such that administration of a vaginal suppository comprising a nitric oxide (NO)-releasing active pharmaceutical ingredient (API) does not result in systemic effects (e.g., adverse systemic effects) from the administration of nitric oxide, e.g., when the vaginal suppository, NO-releasing API, and / or NO are administered in therapeutically effective amounts. In some embodiments, the methods of the present invention are practiced such that administration of a vaginal suppository comprising a nitric oxide-releasing pharmaceutical ingredient produces local and systemic effects from said administration of nitric oxide, e.g., when the vaginal suppository, NO-releasing API, and / or NO are administered in therapeutically effective amounts.

[0069] The terms "prevent," "preventing," and "prevention" (and grammatical conjugations thereof) refer to avoiding, reducing, and / or delaying the onset of a condition (e.g., a viral infection) and / or clinical symptoms associated therewith in a subject, and / or reducing the severity of the onset of the condition and / or clinical symptoms compared to what would occur in the absence of the methods of the invention. The prevention can be complete, e.g., the complete absence of the condition and / or clinical symptoms. The prevention can also be partial, such that the incidence of, and / or the severity of, the condition and / or clinical symptoms in the subject is less than what would occur in the absence of the methods of the invention. In some embodiments, the methods of the invention prevent a viral infection in a subject, e.g., a viral infection that can affect the vagina of the subject.

[0070] In some embodiments, the vaginal suppositories of the present invention are administered in a prophylactically effective amount. As used herein, a "prophylactically effective" amount is an amount sufficient to prevent (as defined herein) the condition (e.g., viral infection) and / or clinical symptoms in the subject. One of ordinary skill in the art will appreciate that the level of prevention need not be complete, as long as some benefit is provided to the subject. In some embodiments, a prophylactically effective amount of the vaginal suppositories of the present invention may be administered, which may include administering a prophylactically effective amount of a nitric oxide-releasing pharmaceutical ingredient. In some embodiments, a prophylactically effective amount of nitric oxide may be administered and / or applied in the methods of the present invention. In some embodiments, the methods of the present invention are carried out such that administration of a vaginal suppository containing an NO-releasing API does not result in systemic effects (e.g., adverse systemic effects) from the administration of nitric oxide, such as when the vaginal suppository, NO-releasing API, and / or NO are administered in prophylactically effective amounts. In some embodiments, the methods of the present invention are practiced such that administration of a vaginal suppository comprising a nitric oxide-releasing pharmaceutical ingredient produces local and systemic effects from said administration of nitric oxide, e.g., when the vaginal suppository, NO-releasing API, and / or NO are administered in prophylactically effective amounts.

[0071] The vaginal suppositories of the present invention can be administered to a subject using any method known to those skilled in the art. In some embodiments, the vaginal suppositories can be administered to the subject at least once, twice, or three or more times per day. In some embodiments, the vaginal suppositories can be administered to the subject at least once, twice, three times, four times, five times, six times, seven times, or eight or more times per week and / or month. In some embodiments, the vaginal suppositories can be administered to the subject once daily, twice daily, every other day, every three days, once per week, or twice per week. In some embodiments, the vaginal suppositories can be administered at least once daily for an extended period of time (e.g., one week, one month, two months, etc.) and / or until the condition (e.g., viral infection) and / or clinical symptoms associated therewith are treated and / or prevented. In some embodiments, the vaginal suppositories can be applied as needed.

[0072] The present invention finds use in both veterinary and medical applications. Suitable subjects of the present invention include, but are not limited to, birds and mammals. As used herein, the term "birds" includes, but is not limited to, chickens, ducks, geese, quail, turkeys, pheasants, parrots, parakeets, macaws, cockatiels, canaries, and finches. As used herein, the term "mammals" includes, but is not limited to, primates (e.g., apes and humans), non-human primates (e.g., monkeys, baboons, chimpanzees, gorillas), bovines, sheep, goats, ungulates, pigs, equines, felines, canines, lagomorphs, pinnipeds, rodents (e.g., rats, hamsters, and mice), and the like. In some embodiments, the subject is a mammal, and in some embodiments, the subject is a human. Human subjects include both males and females and subjects of all ages, including fetal, neonatal, infant, childhood, adolescent, adult, and geriatric subjects.

[0073] The methods of the invention may also be practiced on animal subjects, particularly mammalian subjects such as mice, rats, dogs, cats, livestock and horses, for veterinary purposes and / or for drug screening and drug development purposes.

[0074] In some embodiments, the subject is "in need of" or "in need of" the methods of the invention, e.g., the subject is in an at-risk population (e.g., the subject may be at risk of or more susceptible to viral infection), the subject has a finding typically associated with viral infection, and / or the subject is or is believed to have been exposed to a virus. In some embodiments, the subject in need thereof has a viral infection and / or clinical signs or symptoms associated therewith that can be treated using the methods of the invention. The invention may be particularly suitable for pediatric, adolescent, adult, and / or geriatric subjects.

[0075] In some embodiments, the methods of the present invention may prevent and / or reduce the appearance and / or size of benign lesions. Exemplary benign lesions include, but are not limited to, warts (e.g., genital warts), papillomas, molluscum contagiosum, and / or herpetic lesions. In some embodiments, the benign lesions may be induced and / or caused by papillomaviruses, such as human papillomaviruses.

[0076] The method of the present invention may reduce the appearance and / or size of benign lesions by at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97%, or about 100% compared to the appearance and / or size of the benign lesions before administration of the vaginal suppository of the present invention. The appearance of the benign lesions may be visually assessed, for example, but not limited to, by the subject and / or a physician. The size of the benign lesions may be determined using methods known to those skilled in the art. In some embodiments, the method of the present invention may prevent and / or reduce the appearance and / or size of warts.

[0077] In certain embodiments, the subject may observe a reduction in the size and / or appearance of benign lesions within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 days and / or weeks, or within a longer period of time. In some embodiments, the method may reduce the size and / or appearance of benign lesions in the subject's skin and / or tissues in 12 weeks or less, in some embodiments, within 8 weeks or less, and in further embodiments, within 4 weeks or less.

[0078] The method of the present invention may reduce the number of benign lesions by at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97%, or about 100%, compared to the number of benign lesions before administration of the vaginal suppository of the present invention. The number of benign lesions may be visually assessed, for example, but not limited to, by the subject and / or a physician. The number of benign lesions may be determined using methods known to those skilled in the art. In some embodiments, the method of the present invention may prevent and / or reduce the number of warts.

[0079] The method of the present invention may reduce the rate of recurrence of benign lesions in a subject by at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97%, or about 100%, compared to the rate of recurrence of the same type of benign lesion in the absence of administration of the vaginal suppository of the present invention. The rate of recurrence may be determined using methods known to those skilled in the art. For example, after treatment and / or removal of benign lesions, the number of benign lesions may be visually determined after a given period of time to determine the rate of recurrence. In some embodiments, the method of the present invention may reduce the rate of recurrence of warts in a subject.

[0080] In certain embodiments, the methods of the present invention may prevent and / or reduce the appearance and / or size of premalignant and / or malignant lesions, such as tumors. The premalignant and / or malignant lesions may be caused and / or induced by viral infection. In some embodiments, the premalignant and / or malignant lesions may be premalignant and / or malignant skin lesions. In some embodiments, the premalignant and / or malignant lesions may result from and / or be caused by cervical cancer. In some embodiments, the premalignant and / or malignant lesions may be induced and / or caused by papillomaviruses, such as human papillomaviruses. In some embodiments, the methods of the present invention may prevent and / or reduce the appearance and / or size of cervical intraepithelial neoplasia.

[0081] The methods of the present invention may reduce the appearance and / or size of premalignant and / or malignant lesions by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 97% or more compared to the appearance and / or size of the premalignant and / or malignant lesions prior to administration of the vaginal suppository of the present invention. The appearance of the premalignant and / or malignant lesions may be visually assessed, for example, but not limited to, by the subject and / or a physician. The size of the premalignant and / or malignant lesions may be determined using methods known to those skilled in the art.

[0082] The method of the present invention may reduce the number of premalignant and / or malignant lesions by at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97%, or about 100% compared to the number of premalignant and / or malignant lesions before administration of the vaginal suppository of the present invention. The number of premalignant and / or malignant lesions may be assessed visually by the subject and / or a physician, for example, but not limited to, the number of premalignant and / or malignant lesions may be determined using methods known to those skilled in the art.

[0083] The method of the present invention may reduce the rate of recurrence of premalignant and / or malignant lesions in a subject by at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97%, or about 100%, compared to the rate of recurrence of the same type of premalignant and / or malignant lesions in the absence of administration of the vaginal suppository of the present invention. The rate of recurrence may be determined using methods known to those skilled in the art. For example, after treatment and / or removal of premalignant and / or malignant lesions, the number of premalignant and / or malignant lesions may be visually determined after a given period of time to determine the rate of recurrence.

[0084] In some embodiments, the methods of the present invention may administer nitric oxide to the basal layer of the epithelium of a subject. The methods of the present invention may administer a therapeutically effective amount and / or a prophylactically effective amount of nitric oxide to the basal layer of the epithelium of a subject. In some embodiments, nitric oxide may be administered to the basal layer of the epithelium of a subject.

[0085] In some embodiments, the methods of the present invention may administer nitric oxide in an amount sufficient to induce apoptosis or other cellular damage in cells infected with a virus. In some embodiments, the methods of the present invention may administer nitric oxide in an amount sufficient to inhibit and / or prevent viral replication in cells infected with a virus. The methods of the present invention may reduce viral replication by at least about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 98%, 99%, or 100% compared to the rate of replication before the methods of the present invention.

[0086] In some embodiments, the methods of the present invention may treat and / or prevent a viral infection in a subject without or with reduced cytotoxicity to host cells. The methods may treat and / or prevent a viral infection in a subject with reduced host cell cytotoxicity compared to a different method for treating the viral infection, such as a method that does not administer nitric oxide to the subject's skin and / or tissues or a method that uses acidified nitrite. In some embodiments, the methods of the present invention may reduce host cell cytotoxicity by at least about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 98%, about 99%, or about 100% compared to a different method for treating the viral infection. The methods of the present invention may reduce and / or eliminate viral replication without or with minimal host cell cytotoxicity. For example, the methods may provide host cell cytotoxicity of about 50% or less (e.g., about 40% or less, about 30% or less, about 20% or less, about 10% or less, about 5% or less). Cytotoxicity may be determined using methods known to those skilled in the art, such as qualitative reading of hematoxylin and eosin (H&E) slides, lactate dehydrogenase (LDH) assays, and / or 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assays. In some embodiments, the methods of the present invention may not induce apoptosis. For example, the methods may not induce apoptosis in the keratinocyte layer of the skin and / or tissue.

[0087] In some embodiments, the methods of the present invention may normalize cells in the skin and / or tissue. The cells may be cells that have received a therapeutic and / or preventive effect from the methods of the present invention. For example, the cells may be cells that have been administered nitric oxide according to the methods of the present invention. The cells may normalize, for example, by returning to a normal growth rate and / or complete differentiation. In some embodiments, the methods of the present invention may reduce the number of actively dividing cells throughout the skin and / or tissue, and restrict cell division to the basal layer of the skin and / or tissue, as is the normal physiological state. In some embodiments, the methods of the present invention may restore cells in the skin and / or tissue to a growth rate that prevents the cells, skin, and / or tissue from exhibiting hyperproliferation, hyperplasia (e.g., benign hyperplasia), and / or dysplasia.

[0088] In some embodiments, the virus may cause thickening in the skin and / or tissue area (e.g., the virus may cause warts on the skin), and the methods of the present invention may reduce the thickness of the skin and / or tissue in this area by, for example, at least about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% or more, and / or restore the thickness of the skin and / or tissue in this area to normal. In some embodiments, the methods may reduce the thickness of the thickened area of ​​skin and / or tissue, and / or restore the thickness of the skin and / or tissue in the thickened area to about 20% or less of the normal thickness of the skin and / or tissue. For example, an area of ​​normal skin may have a thickness of 2 mm, and the methods of the present invention may reduce the thickness of the thickened skin in this area to about 2.4 mm to about 2 mm.

[0089] In some embodiments, the methods of the invention may return cells of the skin and / or tissue to normal G2 and / or S phase. For example, a virus may cause cells to have a prolonged G2 phase after re-entering S phase. In some embodiments, the methods of the invention may disrupt and / or interfere with proteins involved in viral replication. For example, the methods of the invention may disrupt and / or interfere with E7 and / or E6 proteins, and / or their interactions and / or signaling. In some embodiments, the methods of the invention may reduce the amount and / or activity of E6 and / or E7 viral proteins. In some embodiments, the methods of the invention may activate and / or increase cellular processes that prevent and / or reduce viral replication.

[0090] In some embodiments, the methods of the invention may reduce the amount of viral DNA in virally infected cells and / or in a subject's vagina. For example, the methods of the invention may reduce the amount of viral DNA by at least about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 98%, about 99%, or about 100% compared to the amount of viral DNA present before the methods of the invention.

[0091] The invention is described in more detail in the following non-limiting examples. [Example]

[0092] Example 1

[0093] [Table 1]

[0094] Ovucire™ / Suppocire™ / Japocire™ are hard fat-based suppository bases used to disperse the active ingredient (NVN3100). These suppository bases can melt in the vaginal cavity, releasing the drug suspended in the base.

[0095] The suppository base selected is hydrophobic because the presence of moisture can cause the release of nitric oxide from NVN3100. The suppository base selected has a low acid value to minimize the release of nitric oxide during manufacturing and / or storage. In some embodiments, the suppository base is present in an amount of 90% or more by weight of the suppository.

[0096] Additional excipients that may be included in the vaginal suppository optionally include a preservative (e.g., paraben) in an amount of about 0.01% to about 1.0% by weight of the suppository, optionally a lubricant (e.g., mineral oil) in an amount of about 1% to about 10% by weight of the suppository, and / or optionally a hard wax in an amount of about 1% to about 10% by weight of the suppository.

[0097] Example 2

[0098] [Table 2]

[0099] The melting range of the suppository can be adjusted using a glycerol-gelatin suppository. Glycerin can help disperse and / or dissolve the API. The ratio of gelatin to glycerin is selected to minimize the presence of water. Care is taken to minimize the inclusion of water in the suppository. In some embodiments, the API can be coated to enable the use of a glycerol-gelatin suppository base. For example, in some embodiments, microencapsulation can be used to minimize degradation of the API and / or premature release of NO from the API. In some embodiments, glycerin is present in an amount of 70% or more by weight of the suppository.

[0100] Additional excipients that may be included in the vaginal suppository optionally include a preservative (e.g., paraben) in an amount of about 0.01% to about 1.0% by weight of the suppository, optionally a lubricant (e.g., mineral oil) in an amount of about 1% to about 10% by weight of the suppository, optionally a hard wax in an amount of about 1% to about 10% by weight of the suppository, and / or optionally one or more additional solvents (e.g., purified water) in an amount of about 1% to about 10% by weight of the suppository.

[0101] Example 3

[0102] [Table 3]

[0103] Cocoa butter (theobroma oil) is a wax base composed of triglycerides of fatty acids and has a melting point of about 31° C. to about 34° C. In some embodiments, the wax base (e.g., cocoa butter) is present in an amount of 90% or more by weight of the suppository.

[0104] Care is taken to minimize overheating during the manufacture of the base, as the base has a tendency to convert into polymorphs with different physicochemical properties. Identifying the source of lower free fatty acids can enhance the stability of the API dispersed in the base.

[0105] Additional excipients that may be included in the vaginal suppository optionally include a preservative (e.g., paraben) in an amount of about 0.01% to about 1.0% by weight of the suppository, optionally a lubricant (e.g., mineral oil) in an amount of about 1% to about 10% by weight of the suppository, and / or optionally a hard wax in an amount of about 1% to about 10% by weight of the suppository.

[0106] Example 4

[0107] [Table 4]

[0108] The suppository may be a monophasic unit dose suppository capable of co-delivering the API and proton source, which may facilitate and / or increase patient compliance. In some embodiments, the suppository base is present in an amount of 60% or more by weight of the suppository.

[0109] A hard fat-based suppository base may be selected that minimizes interaction between the API and one or more buffering agents, which may be selected to have strong buffering capacity at the physiological pH of the vagina and to be a physiologically acceptable buffer.

[0110] Alternatively, the suppository can be designed and manufactured as a multi-layered single-phase system in which the API is stored in the core and the buffer is in an outer layer around the core. Upon insertion into the vaginal cavity, the base melts, releasing the buffer, which provides the protons needed to release nitric oxide from the API dispersed in the core.

[0111] Additional excipients that may be included in the vaginal suppository optionally include a preservative (e.g., paraben) in an amount of about 0.01% to about 1.0% by weight of the suppository, optionally a lubricant (e.g., mineral oil) in an amount of about 1% to about 10% by weight of the suppository, and / or optionally a hard wax in an amount of about 1% to about 10% by weight of the suppository.

[0112] Example 5

[0113] [Table 5]

[0114] The suppository may be a monophasic unit dose suppository capable of co-delivering the API and proton source, which may facilitate and / or increase patient compliance. In some embodiments, the suppository base is present in an amount of 60% or more by weight of the suppository.

[0115] A glycerol-gelatin base can be manufactured in the suppository to minimize interaction of the API with one or more buffers, which can be selected to have strong buffering capacity at the physiological pH of the vagina and to be a physiologically acceptable buffer.

[0116] The suppository may be a multi-layered, single-phase system in which the API is stored in the core and one or more buffering agents are in the outer layer, which may disperse and / or melt rapidly. Upon insertion into the vaginal cavity, the suppository base may melt and / or disperse, thereby releasing the one or more buffering agents, which may provide protons that can be used to release NO from the API dispersed in the core.

[0117] Additional excipients that may be included in the vaginal suppository optionally include a preservative (e.g., paraben) in an amount of about 0.01% to about 1.0% by weight of the suppository, optionally a lubricant (e.g., mineral oil) in an amount of about 1% to about 10% by weight of the suppository, and / or optionally a hard wax in an amount of about 1% to about 10% by weight of the suppository.

[0118] Example 6

[0119] [Table 6]

[0120] The suppository may be a monophasic unit dose suppository capable of co-delivering the API and proton source, which may facilitate and / or increase patient compliance. In some embodiments, the suppository base is present in an amount of 60% or more by weight of the suppository.

[0121] A cocoa butter base can be formulated in the suppository to minimize interaction of the API with one or more buffers, which can be selected to have strong buffering capacity at the physiological pH of the vagina and to be a physiologically acceptable buffer.

[0122] The suppository may be a multi-layered, single-phase system in which the API is stored in the core and one or more buffering agents are in the outer layer, which may disperse and / or melt rapidly. Upon insertion into the vaginal cavity, the suppository base may melt and / or disperse, thereby releasing the one or more buffering agents, which may provide protons that can be used to release NO from the API dispersed in the core.

[0123] Additional excipients that may be included in the vaginal suppository optionally include a preservative (e.g., paraben) in an amount of about 0.01% to about 1.0% by weight of the suppository, optionally a lubricant (e.g., mineral oil) in an amount of about 1% to about 10% by weight of the suppository, and / or optionally a hard wax in an amount of about 1% to about 10% by weight of the suppository.

[0124] Example 7

[0125] [Table 7]

[0126] The suppository may be a monophasic unit dose suppository capable of co-delivering the API and proton source, which may facilitate and / or increase patient compliance. In some embodiments, the suppository base is present in an amount of 70% or more by weight of the suppository.

[0127] A hard fat-based suppository base can be selected to minimize the interaction between the API and one or more buffering agents. The buffering agent can be selected to have a strong buffering capacity at the physiological pH of the vagina and to be a physiologically acceptable buffer. In some embodiments, citric acid is not present in the suppository, and therefore the buffer comprises a phosphate buffer. In some embodiments, both citric acid and potassium dihydrogen phosphate are present in the suppository.

[0128] Alternatively, the suppository can be designed and manufactured as a multi-layered single-phase system in which the API is stored in the core and the buffer is in an outer layer around the core. Upon insertion into the vaginal cavity, the base melts, releasing the buffer that provides the protons needed to release nitric oxide from the API dispersed in the core.

[0129] Additional excipients that may be included in the vaginal suppository optionally include a preservative (e.g., paraben) in an amount of about 0.01% to about 1.0% by weight of the suppository, optionally a lubricant (e.g., mineral oil) in an amount of about 1% to about 10% by weight of the suppository, and / or optionally a hard wax in an amount of about 1% to about 10% by weight of the suppository.

[0130] Example 8

[0131] [Table 8]

[0132] The suppository may be a monophasic unit dose suppository capable of co-delivering the API and proton source, which may facilitate and / or increase patient compliance. In some embodiments, the suppository base is present in an amount of 70% or more by weight of the suppository.

[0133] The glycerol gelatin base can be used in the suppository to minimize the interaction between the API and one or more buffers. The buffer can be selected to have a strong buffering capacity at the physiological pH of the vagina and be physiologically acceptable. In some embodiments, citric acid is not present in the suppository, and therefore the buffer comprises a phosphate buffer. In some embodiments, both citric acid and potassium dihydrogen phosphate are present in the suppository.

[0134] The suppository may be a multi-layered, single-phase system in which the API is stored in the core and one or more buffering agents are in the outer layer, which may disperse and / or melt rapidly. Upon insertion into the vaginal cavity, the suppository base may melt and / or disperse, thereby releasing the one or more buffering agents, which may provide protons that can be used to release NO from the API dispersed in the core.

[0135] Additional excipients that may be included in the vaginal suppository optionally include a preservative (e.g., paraben) in an amount of about 0.01% to about 1.0% by weight of the suppository, optionally a lubricant (e.g., mineral oil) in an amount of about 1% to about 10% by weight of the suppository, and / or optionally a hard wax in an amount of about 1% to about 10% by weight of the suppository.

[0136] Example 9

[0137] [Table 9]

[0138] The suppository may be a monophasic unit dose suppository capable of co-delivering the API and proton source, which may facilitate and / or increase patient compliance. In some embodiments, the suppository base is present in an amount of 70% or more by weight of the suppository.

[0139] The cocoa butter base can be prepared in the suppository to minimize the interaction between the API and one or more buffers. The buffer can be selected to have a strong buffering capacity at the physiological pH of the vagina and be physiologically acceptable. In some embodiments, citric acid is not present in the suppository, and therefore the buffer comprises a phosphate buffer. In some embodiments, both citric acid and potassium dihydrogen phosphate are present in the suppository.

[0140] The suppository may be a multi-layered, single-phase system in which the API is stored in the core and one or more buffering agents are in the outer layer, which may disperse and / or melt rapidly. Upon insertion into the vaginal cavity, the suppository base may melt and / or disperse, thereby releasing the one or more buffering agents, which may provide protons that can be used to release NO from the API dispersed in the core.

[0141] Additional excipients that may be included in the vaginal suppository optionally include a preservative (e.g., paraben) in an amount of about 0.01% to about 1.0% by weight of the suppository, optionally a lubricant (e.g., mineral oil) in an amount of about 1% to about 10% by weight of the suppository, and / or optionally a hard wax in an amount of about 1% to about 10% by weight of the suppository.

[0142] The foregoing is illustrative of the invention and should not be construed as limiting thereof. The invention is defined by the following claims, of which equivalents are to be encompassed. All publications, patent applications, patents, patent publications, and other references cited herein are incorporated by reference in their entirety for the teachings associated with the sentence and / or paragraph in which the reference is presented.

[0143] One embodiment of the present invention is as follows. [Section 1] Nitric oxide-releasing active pharmaceutical ingredient Suppository base and A vaginal suppository containing: [Section 2] Item 2. The vaginal suppository according to Item 1, wherein the nitric oxide-releasing active pharmaceutical ingredient is present in an amount of about 0.1% by weight to about 10% by weight, about 20% by weight, about 30% by weight, about 40% by weight, about 50% by weight, about 60% by weight, or about 70% by weight of the vaginal suppository. [Section 3] Item 3. The vaginal suppository according to Item 1 or 2, wherein the vaginal suppository releases nitric oxide in an amount of about 0.01% to about 10% by weight of the vaginal suppository when measured by a real-time in vitro release test. [Section 4] Item 4. The vaginal suppository according to any one of Items 1 to 3, wherein the suppository base is present in an amount of about 0.01% to about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 99%, or about 99.1% of the vaginal suppository, and optionally, the suppository base is present in an amount of at least about 70% of the vaginal suppository. [Section 5] The suppository base is cocoa butter, C8 to C 20 triglyceride, monoglyceride and diglyceride esters of fatty acids and mixtures thereof, gelatin, polyethylene glycol (PEG), and / or glycerolized glycerin; Item 5. The vaginal suppository according to any one of Items 1 to 4, wherein the fatty acid includes capric acid, caprylic acid, eicosenoic acid, stearic acid, lauric acid, myristic acid, oleic acid, palmitic acid, ricinoleic acid, and derivatives thereof. [Section 6] Item 6. The vaginal suppository according to any one of Items 1 to 5, wherein the suppository base is hydrophobic or hydrophilic. [Section 7] The vaginal suppository contains about 0.1% by weight to about 0.5% by weight, about 1% by weight, about 2% by weight, about 3% by weight, about 4% by weight, about 5% by weight, about 6% by weight, about 7% by weight, about 8% by weight, about 9% by weight, about 10% by weight, about 11% by weight, about 12% by weight, about 13% by weight, about 14% by weight, about 15% by weight, about 16% by weight Item 7. The vaginal suppository according to any one of Items 1 to 6, further comprising a buffering agent in an amount of about 17% by weight, about 18% by weight, about 19% by weight, about 20% by weight, about 21% by weight, about 22% by weight, about 23% by weight, about 24% by weight, about 25% by weight, about 26% by weight, about 27% by weight, about 28% by weight, about 29% by weight, or about 30% by weight. [Section 8] the vaginal suppository comprises at least two buffering agents; and each of the at least two buffering agents is present in an amount of about 0.1% to about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, or about 30% by weight of the vaginal suppository; Item 8. The vaginal suppository according to any one of Items 1 to 7. [Section 9] Item 9. The vaginal suppository according to any one of Items 1 to 8, wherein the buffering agent comprises potassium dihydrogen phosphate, phosphoric acid, citric acid, acetic acid, lactic acid, boric acid, succinic acid, malic acid, sodium citrate dihydrate, and any combination thereof. [Section 10] Item 10. The vaginal suppository according to any one of Items 7 to 9, wherein the buffering agent has a buffering capacity at physiological vaginal pH. [Section 11] Item 11. The vaginal suppository according to any one of Items 1 to 10, further comprising a preservative in an amount of about 0.1% to about 0.2%, about 0.3% by weight, about 0.4% by weight, about 0.5% by weight, about 0.6% by weight, about 0.7% by weight, about 0.8% by weight, about 0.9% by weight, about 1% by weight, about 1.1% by weight, about 1.2% by weight, about 1.3% by weight, about 1.4% by weight, about 1.5% by weight, about 1.6% by weight, about 1.7% by weight, about 1.8% by weight, about 1.9% by weight, or about 2% by weight of the vaginal suppository. [Section 12] The preservative may be sorbic acid, benzoic acid, methyl-paraben, propyl-paraben, methylchloroisothiazolinone, methylisothiazolinone, diazolidinyl urea, chlorobutanol, triclosan, benzethonium chloride, p-hydroxybenzoic acid esters, chlorhexidine, digluconate, hexadecyltrimethylammonium bromide, alcohols, benzalkonium chloride, boric acid, bronopol, butylparaben, calcium butylene acetate, calcium chloride, calcium lactate, carbon dioxide, cationic and bentonite, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, citric acid monohydrate, Item 12. The vaginal suppository according to Item 11, comprising cresol, dimethyl ether, ethylparaben, glycerin, hexetidine, imidurea, isopropyl alcohol, lactic acid, monothioglycerol, pentetic acid, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, potassium benzoate, potassium metabisulfite, potassium sorbate, propionic acid, propyl gallate, propylene glycol, sodium acetate, sodium benzoate, sodium borate, sodium lactate, sodium sulfite, sodium propionate, sodium metabisulfite, xylitol, sulfur dioxide, carbon dioxide, and any combination thereof. [Section 13] Item 13. The vaginal suppository according to any one of Items 1 to 12, further comprising a solvent in an amount of about 0.1% by weight to about 1% by weight, about 5% by weight, about 10% by weight, about 20% by weight, about 30% by weight, about 40% by weight, about 50% by weight, about 60% by weight, about 70% by weight, about 80% by weight, about 90% by weight, or about 99% by weight of the vaginal suppository. [Section 14] Item 14. The vaginal suppository according to Item 13, wherein the solvent includes acetone, methyl alcohol, ethanol, isopropanol, butyl alcohol, ethyl acetate, dimethyl isosorbide, propylene glycol, glycerin, ethylene glycol, polyethylene glycol, diethylene glycol monoethyl ether, water (e.g., purified and / or sterilized water), and mixtures thereof. [Section 15] Item 15. The vaginal suppository according to any one of Items 1 to 14, further comprising a lubricant in an amount of about 1% to about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10% by weight of the vaginal suppository. [Section 16] Item 16. The vaginal suppository according to Item 15, wherein the lubricant comprises magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oil, Sterotex, polyoxyethylene monostearate, talc, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, and mineral oil, or a combination thereof. [Section 17] Item 17. The vaginal suppository according to any one of Items 1 to 16, further comprising mineral oil in an amount of about 1% by weight to about 2% by weight, about 3% by weight, about 4% by weight, about 5% by weight, about 6% by weight, about 7% by weight, about 8% by weight, about 9% by weight, about 10% by weight, about 11% by weight, about 12% by weight, about 13% by weight, about 14% by weight, about 15% by weight, about 16% by weight, about 17% by weight, about 18% by weight, about 19% by weight, or about 20% by weight of the vaginal suppository. [Section 18] Item 18. The vaginal suppository according to any one of Items 1 to 17, further comprising one or more hard waxes in an amount of about 1% by weight to about 2% by weight, about 3% by weight, about 4% by weight, about 5% by weight, about 6% by weight, about 7% by weight, about 8% by weight, about 9% by weight, about 10% by weight, about 11% by weight, about 12% by weight, about 13% by weight, about 14% by weight, about 15% by weight, about 16% by weight, about 17% by weight, about 18% by weight, about 19% by weight, or about 20% by weight of the vaginal suppository. [Section 19] Item 19. The vaginal suppository according to any one of items 1 to 18, wherein the nitric oxide-releasing active pharmaceutical ingredient comprises a co-condensed silica network comprising diazeniumdiolated methylaminopropyltrimethoxysilane (MAP3) and tetraethyl orthosilicate (TEOS). [Section 20] Item 20. The vaginal suppository according to any one of items 1 to 19, wherein the nitric oxide-releasing active pharmaceutical ingredient comprises a co-condensed silica network comprising diazeniumdiolated methylaminopropyltrimethoxysilane (MAP3), ethylaminoisobutylsiloxane (EAIB3), and tetraethyl orthosilicate (TEOS). [Section 21] Item 21. The vaginal suppository of any one of Items 1 to 20, wherein the vaginal suppository administers nitric oxide in an amount sufficient to induce apoptosis in virus-infected cells. [Section 22] 22. The vaginal suppository of any one of paragraphs 1 to 21, wherein the vaginal suppository administers nitric oxide in an amount sufficient to reduce or eliminate viral replication with less than about 50% host cell cytotoxicity. [Section 23] Item 23. A method of using the vaginal suppository according to any one of Items 1 to 22 for treating and / or preventing an infection (e.g., a viral infection) in a subject in need thereof. [Section 24] Compounds, compositions, articles of manufacture, and / or methods substantially as shown and / or described herein.

[0144] Another embodiment of the present invention is as follows. [Section A1] a nitric oxide-releasing active pharmaceutical ingredient, wherein the nitric oxide-releasing active pharmaceutical ingredient is a polymer including a crosslinked or non-crosslinked polymer, a dendrimer, a metal compound, an organometallic compound, or an inorganic compound; Suppository base and A suppository comprising: the nitric oxide-releasing active pharmaceutical ingredient is in a suppository base; The suppository releases nitric oxide in an amount of about 0.01% to about 10% by weight of the suppository as measured by a real-time in vitro release test. The suppository. [Section A2] The suppository according to Item A1, wherein the nitric oxide-releasing active pharmaceutical ingredient is present in an amount of about 0.1% to about 70% by weight of the suppository. [Section A3] The suppository according to item A1 or A2, wherein the suppository base is present in an amount of about 0.01% to about 99.1% of the suppository, and optionally, the suppository base is present in an amount of at least about 70% of the suppository. [Section A4] The suppository base is cocoa butter, C8 to C 20 triglyceride, monoglyceride and diglyceride esters of fatty acids and mixtures thereof, gelatin, polyethylene glycol (PEG), and / or glycerolized glycerin; The suppository according to any one of Items A1 to A3, wherein the fatty acids include capric acid, caprylic acid, eicosenoic acid, stearic acid, lauric acid, myristic acid, oleic acid, palmitic acid, ricinoleic acid, and derivatives thereof. [Section A5] The suppository according to any one of items A1 to A4, wherein the suppository base is hydrophobic or hydrophilic. [Section A6] The suppository according to any one of items A1 to A5, further comprising a buffer in an amount of about 0.1% to about 30% by weight of the suppository. [Section A7] the suppository comprises at least two buffering agents, and Each of the at least two buffering agents is present in an amount of about 0.1% to about 30% by weight of the suppository. The suppository according to any one of Items A1 to A6. [Section A8] The suppository according to any one of items A1 to A7, wherein the buffering agent includes potassium dihydrogen phosphate, phosphoric acid, citric acid, acetic acid, lactic acid, boric acid, succinic acid, malic acid, sodium citrate dihydrate, and any combination thereof. [Section A9] The suppository according to any one of items A6 to A8, wherein the buffer has a buffering capacity at physiological pH. [Section A10] The suppository according to any one of items A1 to A9, further comprising a preservative in an amount of about 0.1% to about 2% by weight of the suppository. [Section A11] The preservative may be sorbic acid, benzoic acid, methyl-paraben, propyl-paraben, methylchloroisothiazolinone, methylisothiazolinone, diazolidinyl urea, chlorobutanol, triclosan, benzethonium chloride, p-hydroxybenzoic acid esters, chlorhexidine, digluconate, hexadecyltrimethylammonium bromide, alcohols, benzalkonium chloride, boric acid, bronopol, butylparaben, calcium butylene acetate, calcium chloride, calcium lactate, carbon dioxide, cationic and bentonite, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, citric acid monohydrate, The suppository according to paragraph A10, which includes cresol, dimethyl ether, ethylparaben, glycerin, hexetidine, imidurea, isopropyl alcohol, lactic acid, monothioglycerol, pentetic acid, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, potassium benzoate, potassium metabisulfite, potassium sorbate, propionic acid, propyl gallate, propylene glycol, sodium acetate, sodium benzoate, sodium borate, sodium lactate, sodium sulfite, sodium propionate, sodium metabisulfite, xylitol, sulfur dioxide, carbon dioxide, and any combination thereof. [Section A12] The suppository according to any one of items A1 to A11, further comprising a solvent in an amount of about 0.1% to about 99% by weight of the suppository. [Section A13] The suppository according to item A12, wherein the solvent includes acetone, methyl alcohol, ethanol, isopropanol, butyl alcohol, ethyl acetate, dimethyl isosorbide, propylene glycol, glycerin, ethylene glycol, polyethylene glycol, diethylene glycol monoethyl ether, water, and mixtures thereof. [Section A14] The suppository according to any one of items A1 to A13, further comprising a lubricant in an amount of about 1% to about 10% by weight of the suppository. [Section A15] The suppository according to item A14, wherein the lubricant includes magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oil, Sterotex, polyoxyethylene monostearate, talc, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, and mineral oil, or a combination thereof. [Section A16] The suppository according to any one of items A1 to A15, further comprising mineral oil in an amount of about 1% to about 20% by weight of the suppository. [Section A17] The suppository according to any one of items A1 to A16, further comprising one or more hard waxes in an amount of about 1% to about 20% by weight of the suppository. [Section A18] The suppository according to any one of items A1 to A17, wherein the nitric oxide-releasing active pharmaceutical ingredient comprises a co-condensed silica network comprising diazeniumdiolated methylaminopropyltrimethoxysilane (MAP3) and tetraethyl orthosilicate (TEOS). [Section A19] The suppository according to any one of paragraphs A1 to A18, wherein the nitric oxide-releasing active pharmaceutical ingredient comprises a co-condensed silica network comprising diazeniumdiolated methylaminopropyltrimethoxysilane (MAP3), ethylaminoisobutylsiloxane (EAIB3), and tetraethyl orthosilicate (TEOS). [Section A20] The suppository according to any one of paragraphs A1 to 19, wherein the suppository administers nitric oxide in an amount sufficient to induce apoptosis in virus-infected cells. [Section A21] The suppository according to any one of paragraphs A1 to A20, wherein the suppository administers nitric oxide in an amount sufficient to reduce or eliminate viral replication with less than about 50% host cell cytotoxicity. [Section A22] The suppository according to any one of items A1 to A21, wherein the suppository is a vaginal suppository. [Section A23] The suppository according to any one of items A1 to A22, for treating and / or preventing an infection in a subject in need thereof. [Section A24] The suppository according to item A23, wherein the infection is a viral infection.

Claims

1. A suppository, comprising: a nitric oxide-releasing active pharmaceutical ingredient, wherein said nitric oxide-releasing active pharmaceutical ingredient comprises a co-condensed silica network; and a suppository base, wherein the suppository base is C ８ ~C ２０ suppository bases comprising monoglyceride and diglyceride esters of fatty acids and mixtures thereof, gelatin, polyethylene glycol (PEG), and / or glycerolized glycerin, and wherein the suppository base is present in an amount of 75% to 99.9% by weight of the suppository. Including, the nitric oxide-releasing active pharmaceutical ingredient is dispersed in a suppository base; the co-condensed silica network comprises diazeniumdiolated methylaminopropyltrimethoxysilane (MAP3) and tetraethyl orthosilicate (TEOS); and the nitric oxide-releasing active pharmaceutical ingredient is present in an amount of about 0.1% to about 10% by weight of the suppository; The suppository.

2. 10. The suppository of claim 1, wherein the nitric oxide-releasing active pharmaceutical ingredient is present in an amount of about 0.1% to about 5% by weight of the suppository.

3. 3. The suppository of claim 1, wherein the suppository base is present in an amount of 80% to 99.9% by weight of the suppository.

4. 4. The suppository according to claim 1, wherein the fatty acids include capric acid, caprylic acid, eicosenoic acid, stearic acid, lauric acid, myristic acid, oleic acid, palmitic acid, ricinoleic acid, and derivatives thereof.

5. The suppository according to any one of claims 1 to 4, wherein the suppository base is hydrophobic or hydrophilic.

6. The suppository of any one of claims 1 to 5, further comprising a buffering agent in an amount of about 0.1% to about 30% by weight of the suppository.

7. the suppository further comprises at least two buffering agents; and each of the at least two buffering agents is present in an amount of about 0.1% to about 30% by weight of the suppository; The suppository according to any one of claims 1 to 6.

8. 8. The suppository of claim 6 or 7, wherein the buffering agent comprises potassium dihydrogen phosphate, phosphoric acid, citric acid, acetic acid, lactic acid, boric acid, succinic acid, malic acid, sodium citrate dihydrate, and any combination thereof.

9. The suppository according to any one of claims 6 to 8, wherein the buffering agent has buffering capacity at physiological pH.

10. 10. The suppository of any one of claims 1 to 9, further comprising a preservative in an amount of about 0.1% to about 2% by weight of the suppository.

11. The preservative may be sorbic acid, benzoic acid, methyl-paraben, propyl-paraben, methylchloroisothiazolinone, methylisothiazolinone, diazolidinyl urea, chlorobutanol, triclosan, benzethonium chloride, p-hydroxybenzoic acid esters, chlorhexidine, digluconate, hexadecyltrimethylammonium bromide, alcohols, benzalkonium chloride, boric acid, bronopol, butylparaben, calcium butylene acetate, calcium chloride, calcium lactate, carbon dioxide, bentonite, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, citric acid monohydrate, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, citric acid monohydrate, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, citric acid monohydrate, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, citric acid monohydrate, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, chlorhexidine, chlorohexanol ...

11. The suppository of claim 10, comprising resole, dimethyl ether, ethylparaben, glycerin, hexetidine, imidurea, isopropyl alcohol, lactic acid, monothioglycerol, pentetic acid, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, potassium benzoate, potassium metabisulfite, potassium sorbate, propionic acid, propyl gallate, propylene glycol, sodium acetate, sodium benzoate, sodium borate, sodium lactate, sodium sulfite, sodium propionate, sodium metabisulfite, xylitol, sulfur dioxide, and any combination thereof.

12. The suppository of any one of claims 1 to 11, further comprising a solvent in an amount of about 0.1% to about 99% by weight of the suppository.

13. 13. The suppository of claim 12, wherein the solvent comprises acetone, methyl alcohol, ethanol, isopropanol, butyl alcohol, ethyl acetate, dimethyl isosorbide, propylene glycol, glycerin, ethylene glycol, polyethylene glycol, diethylene glycol monoethyl ether, water, and mixtures thereof.

14. 14. The suppository of any one of claims 1 to 13, further comprising a lubricant in an amount of about 1% to about 10% by weight of the suppository.

15. 15. The suppository of claim 14, wherein the lubricant comprises magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oil, Sterotex, polyoxyethylene monostearate, talc, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, and mineral oil, or a combination thereof.

16. 16. The suppository of any one of claims 1 to 15, further comprising mineral oil in an amount of about 1% to about 20% by weight of the suppository.

17. 17. The suppository of any one of claims 1 to 16, further comprising one or more hard waxes in an amount of about 1% to about 20% by weight of the suppository.

18. 18. The suppository of any one of claims 1 to 17, wherein the co-condensed silica network further comprises ethylaminoisobutylsiloxane (EAIB3).

19. 19. The suppository of any one of claims 1 to 18, wherein the suppository administers nitric oxide in an amount sufficient to induce apoptosis in virally infected cells.

20. 20. The suppository of any one of claims 1-19, wherein the suppository administers nitric oxide in an amount sufficient to reduce or eliminate viral replication with less than about 50% host cell cytotoxicity.

21. The suppository according to any one of claims 1 to 20, wherein the suppository is a vaginal suppository.

22. The suppository according to any one of claims 1 to 21 for treating and / or preventing an infection in a subject in need thereof.

23. 23. The suppository of claim 22, wherein the infection is a viral infection.

24. The suppository according to any one of claims 1 to 23, wherein the nitric oxide-releasing active pharmaceutical ingredient is a polymer having a molecular weight of 500 daltons or more.

25. A suppository described in any one of claims 1 to 24, wherein the suppository is an anhydrous suppository.

26. A suppository described in any one of claims 1 to 25, wherein the suppository has a water content of less than 5% by weight of the suppository.

Images